{"id":180383,"date":"2026-02-11T06:40:31","date_gmt":"2026-02-11T11:40:31","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=180383"},"modified":"2026-02-11T06:40:33","modified_gmt":"2026-02-11T11:40:33","slug":"hikal-limited-reports-q3-fy26-loss-after-exceptional-charges-interim-dividend-declared","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/hikal-limited-reports-q3-fy26-loss-after-exceptional-charges-interim-dividend-declared\/","title":{"rendered":"Hikal Limited reports Q3 FY26 loss after exceptional charges; interim dividend declared"},"content":{"rendered":"\n<p><strong>Hikal Limited (NSE: HIKAL, BSE: 524735)<\/strong> reported a loss for the quarter ended Dec. 31, 2025, after booking exceptional charges linked to labour code-related provisions, while revenue rose sequentially. The board also declared an interim dividend, according to the company\u2019s regulatory filing and unaudited results for Q3 and 9M FY26.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Q3 FY26 financial performance<\/h2>\n\n\n\n<p>On a standalone basis, <strong>revenue from operations rose to \u20b94,943 million<\/strong> in Q3 FY26 from <strong>\u20b93,185 million in Q2 FY26<\/strong>, reflecting a sequential recovery in volumes. Year on year, revenue was higher than <strong>\u20b94,477 million<\/strong> reported in Q3 FY25.<\/p>\n\n\n\n<p><strong>Profit before tax (before exceptional items) stood at \u20b9288 million<\/strong>, compared with a loss in the preceding quarter. However, the company booked <strong>exceptional charges of \u20b9380 million<\/strong> in Q3 FY26, primarily related to incremental employee benefit provisions following the notification of India\u2019s new labour codes. As a result, <strong>profit before tax after exceptional items turned into a loss of \u20b992 million<\/strong>, and <strong>net loss for the quarter was \u20b959 million<\/strong>.<\/p>\n\n\n\n<p>Finance costs declined sequentially to <strong>\u20b9155 million<\/strong> from \u20b9149 million in Q2 FY26, while depreciation and amortisation stood at <strong>\u20b9412 million<\/strong>. The company reported <strong>basic and diluted EPS of -\u20b90.48<\/strong> for the quarter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Nine-month FY26 performance<\/h2>\n\n\n\n<p>For the nine months ended Dec. 31, 2025, <strong>revenue from operations declined to \u20b911,932 million<\/strong> from <strong>\u20b913,074 million<\/strong> in the year-ago period. <strong>Profit before tax before exceptional items was a loss of \u20b9487 million<\/strong>, reflecting pressure on margins across segments and lower volumes in parts of the year.<\/p>\n\n\n\n<p>After accounting for <strong>exceptional charges of \u20b9380 million<\/strong>, <strong>net loss for 9M FY26 widened to \u20b9633 million<\/strong>. The company attributed part of the performance pressure to softer demand in certain markets and higher operating costs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Segment performance<\/h2>\n\n\n\n<p>The <strong>pharmaceuticals segment<\/strong> generated <strong>\u20b93,373 million of revenue in Q3 FY26<\/strong>, up sequentially from \u20b91,895 million, while <strong>crop protection contributed \u20b91,570 million<\/strong>, compared with \u20b91,290 million in the previous quarter. For 9M FY26, pharmaceuticals revenue stood at <strong>\u20b97,294 million<\/strong>, and crop protection at <strong>\u20b94,638 million<\/strong>.<\/p>\n\n\n\n<p>Segment results showed <strong>pharmaceuticals delivered a profit of \u20b9415 million in Q3 FY26<\/strong>, while <strong>crop protection recorded \u20b948 million<\/strong>, indicating a sequential improvement in operating performance across both segments.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Dividend and corporate actions<\/h2>\n\n\n\n<p>The board declared an <strong>interim dividend of 10%<\/strong>, equivalent to <strong>\u20b90.20 per equity share (face value \u20b92)<\/strong>, for FY26. The <strong>record date is Feb. 17, 2026<\/strong>, and the dividend is scheduled to be paid on or before <strong>March 12, 2026<\/strong>. The trading window for designated persons is set to reopen on <strong>Feb. 14, 2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Regulatory and operational developments<\/h2>\n\n\n\n<p>The company disclosed that sales in the pharmaceutical segment were impacted following a <strong>USFDA warning letter issued in August 2025<\/strong> for its Jigani facility, with some customers deferring purchases to later quarters.<\/p>\n\n\n\n<p>Hikal also noted that a <strong>fact-finding review<\/strong> is ongoing regarding <strong>irregularities in the timing of revenue recognition<\/strong> identified earlier in FY26. Pending the outcome, no further adjustments have been made to the financials. Additionally, legacy matters related to <strong>environmental compliance<\/strong> remain pending before the Supreme Court, with no incremental provisions recorded during the quarter.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Summary<\/h2>\n\n\n\n<p>Hikal reported a sequential rebound in Q3 FY26 revenue but posted a net loss after exceptional charges related to labour code-linked employee benefit provisions. Segment-level profitability improved sequentially in pharmaceuticals and crop protection. The interim dividend declaration underscores balance-sheet resilience, while regulatory developments and ongoing reviews remain key near-term overhangs for the company\u2019s operating outlook.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hikal Limited (NSE: HIKAL, BSE: 524735) reported a loss for the quarter ended Dec. 31, 2025, after booking exceptional charges linked to labour code-related provisions, while revenue rose sequentially. The board also declared an interim dividend, according to the company\u2019s regulatory filing and unaudited results for Q3 and 9M FY26. Q3 FY26 financial performance On [&hellip;]<\/p>\n","protected":false},"author":2409,"featured_media":125269,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5,1941,392],"tags":[16274,16260,16275],"class_list":["post-180383","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest","category-stock-analysis","category-earnings","tag-agrochemicals-and-crop-protection","tag-pharmaceutical-manufacturing","tag-specialty-chemicals-industry"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":142188,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-hikal-limited-for-q3-fy23\/","url_meta":{"origin":180383,"position":0},"title":"Earnings Summary Of Hikal Limited For Q3 FY23","author":"Hardik Bhandare","date":"February 17, 2023","format":false,"excerpt":"Hikal Limited (NSE: HIKAL) is a leading Indian life sciences company with a global presence. The company specializes in developing and manufacturing intermediates, active pharmaceutical ingredients (APIs), and specialty chemicals for the pharmaceutical, agrochemical, and animal health industries. HIKAL has a strong focus on innovation and quality, which has helped\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-1-3.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179436,"url":"https:\/\/alphastreet.com\/india\/saregama-india-ltd-shares-fall-as-q3-fy26-revenue-and-profit-decline\/","url_meta":{"origin":180383,"position":1},"title":"Saregama India Ltd Shares Fall as Q3 FY26 Revenue and Profit Decline","author":"Staff Correspondent","date":"February 3, 2026","format":false,"excerpt":"Saregama India Limited (SAREGAMA.NS) shares closed at \u20b9328.00 on the National Stock Exchange on Tuesday, down about 0.49% on the day, with the company\u2019s market capitalization at approximately \u20b96,305 crore at the close of trading. Saregama reported third-quarter fiscal 2026 earnings for the period ended Dec. 31, 2025, showing declines\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180311,"url":"https:\/\/alphastreet.com\/india\/suprajit-engineering-delivers-strong-q3-fy26-amid-challenges\/","url_meta":{"origin":180383,"position":2},"title":"Suprajit Engineering Delivers Strong Q3 FY26 Amid Challenges","author":"Staff Correspondent","date":"February 10, 2026","format":false,"excerpt":"Suprajit Engineering Limited (NSE: SUPRAJIT) reported robust consolidated performance for Q3 FY26, outpacing industry growth despite global headwinds. The company declared a 150% interim dividend, up from 125% last year. Consolidated Financials Consolidated revenue excluding SCS entities reached \u20b98,589 million in Q3 FY26, marking 9.8% year-over-year growth, while EBITDA stood\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180706,"url":"https:\/\/alphastreet.com\/india\/pi-industries-limited-investor-update-financial-snapshot\/","url_meta":{"origin":180383,"position":3},"title":"PI Industries Limited Investor Update Financial Snapshot","author":"Staff Correspondent","date":"February 13, 2026","format":false,"excerpt":"Headline Numbers During Q3 FY26, consolidated revenue stood at \u20b913,757 million, compared with \u20b919,008 million in Q3 FY25, reflecting a 28% year-on-year decline. EBITDA for the quarter was \u20b93,027 million, with a margin of 22%, versus \u20b95,122 million and a margin of 27% in the prior year period. Net profit\u2026","rel":"","context":"In &quot;Industrials&quot;","block_context":{"text":"Industrials","link":"https:\/\/alphastreet.com\/india\/category\/industrials\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":180381,"url":"https:\/\/alphastreet.com\/india\/entertainment-network-india-limited-sees-q3-fy26-revenue-growth-led-by-digital-and-ip-ad-market-pressure-weighs-on-ebitda\/","url_meta":{"origin":180383,"position":4},"title":"Entertainment Network (India) Limited sees Q3 FY26 revenue growth led by digital and IP; ad market pressure weighs on EBITDA","author":"Staff Correspondent","date":"February 11, 2026","format":false,"excerpt":"Entertainment Network (India) Limited (NSE: ENIL, BSE: 532700) reported modest revenue growth in the December quarter, driven by sharp gains in digital and IP-led businesses, while profitability declined due to higher operating costs and continued stress in the radio advertising market, according to the company\u2019s Q3 FY26 investor presentation. Q3\u2026","rel":"","context":"In &quot;LATEST&quot;","block_context":{"text":"LATEST","link":"https:\/\/alphastreet.com\/india\/category\/latest\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":177629,"url":"https:\/\/alphastreet.com\/india\/onesource-specialty-pharma-ltd-reports-q3-fy26-revenue-of-%e2%82%b92-9-billion-ebitda-declines-amid-approval-delays\/","url_meta":{"origin":180383,"position":5},"title":"OneSource Specialty Pharma Ltd reports Q3 FY26 revenue of \u20b92.9 billion, EBITDA declines amid approval delays","author":"Staff Correspondent","date":"January 24, 2026","format":false,"excerpt":"OneSource Specialty Pharma Ltd (BSE: 544292 \/ NSE: ONESOURCE) reported consolidated revenue of \u20b92.9 billion for the quarter ended December 31, 2025, a decline of 26% year-on-year, according to its Q3 FY26 earnings release. EBITDA stood at \u20b9173 million, down 88% from the corresponding quarter last year, while adjusted profit\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2409"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=180383"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180383\/revisions"}],"predecessor-version":[{"id":180384,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/180383\/revisions\/180384"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125269"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=180383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=180383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=180383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}